Q3 Earnings Forecast for Biofrontera Issued By Roth Capital

Biofrontera Inc. (NASDAQ:BFRI) – Equities researchers at Roth Capital raised their Q3 2025 EPS estimates for Biofrontera in a research note issued on Monday, June 30th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their prior estimate of ($0.31). The consensus estimate for Biofrontera’s current full-year earnings is ($3.01) per share. Roth Capital also issued estimates for Biofrontera’s Q4 2025 earnings at $0.19 EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at $0.17 EPS, FY2027 earnings at $0.40 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $1.12 EPS.

Biofrontera (NASDAQ:BFRI) last announced its earnings results on Thursday, May 15th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.33). Biofrontera had a negative return on equity of 305.13% and a negative net margin of 30.33%. The company had revenue of $8.59 million for the quarter, compared to analyst estimates of $10.55 million.

Separately, Benchmark lowered their price target on shares of Biofrontera from $7.00 to $2.75 and set a “buy” rating for the company in a report on Monday, May 19th.

Biofrontera Price Performance

Biofrontera stock opened at $0.71 on Thursday. The stock’s 50 day moving average is $0.66 and its 200 day moving average is $0.87. Biofrontera has a one year low of $0.54 and a one year high of $2.22. The firm has a market cap of $6.67 million, a P/E ratio of -0.31 and a beta of 0.43. The company has a debt-to-equity ratio of 8.99, a current ratio of 1.40 and a quick ratio of 0.80.

Hedge Funds Weigh In On Biofrontera

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Biofrontera during the 4th quarter worth about $48,000. AIGH Capital Management LLC boosted its position in shares of Biofrontera by 61.8% during the 4th quarter. AIGH Capital Management LLC now owns 811,097 shares of the company’s stock valued at $884,000 after purchasing an additional 309,663 shares in the last quarter. Finally, Rosalind Advisors Inc. grew its stake in Biofrontera by 63.9% during the fourth quarter. Rosalind Advisors Inc. now owns 811,918 shares of the company’s stock worth $885,000 after purchasing an additional 316,428 shares during the period. Institutional investors and hedge funds own 10.08% of the company’s stock.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.